Navigation Links
Further doubt cast on virus link to chronic fatigue

Researchers investigating UK samples have found no association between the controversial xenotropic murine leukaemia virus-related virus (XMRV) and chronic fatigue syndrome (CFS). Their study, published in BioMed Central's open access journal Retrovirology, calls into question a potential link described late last year by an American research team.

Kate Bishop from the MRC National Institute for Medical Research worked with a team of researchers to test blood and serum samples from 170 CFS patients and 395 healthy controls, using quantitative PCR and a virus neutralization assay. She said, "No association between XMRV infection and CFS was observed in the samples tested, either by PCR or serological methodologies. Our findings therefore appear inconsistent with the previous report that isolated XMRV from the blood cells of CFS patients. We are confident that, although we were unable to replicate the detection, our PCR assay is more sensitive than the earlier method and possessed the necessary sensitivity to detect XMRV had it been present".

Bishop and her colleagues point out that CFS likely encompasses a range of diseases, and it is still possible that some of them might be associated with XMRV infection. They say, "There has been much discussion and controversy amongst CFS researchers and patients alike, which highlights the need for additional investigations in this area. Following our findings, it would seem a prudent next step for subsequent studies to compare samples and protocols between different laboratories around the world".

The findings of this Retrovirology study are supported by results from a recently published work from Imperial College London that also found no proof that XMRV infection is associated with CFS.


Contact: Graeme Baldwin
BioMed Central

Page: 1

Related biology news :

1. Further development of Water Framework Directive necessary
2. Further breakthroughs for breast cancer patients
3. Worlds largest investor coalition seeks further disclosure on climate change and shareholder value
4. Immunosuppressant further linked to birth defects
5. New study casts further doubt on risk of death from higher salt intake
6. New CITES quotas allow more caviar export, further jeopardize endangered sturgeon
7. UNC, Caltech research finds further evidence for genetic contribution to autism
8. New book further supports controversial theory of Man the Hunted
9. Characterization of grapevine transposons furthers understanding of in vino variety
10. New study provides further evidence that apple juice can delay onset of Alzheimers disease
11. Researcher garners major award from NIH for further exploration into the mechanisms of obesity
Post Your Comments:
(Date:10/4/2017)... 4, 2017  GCE Solutions, a global clinical research organization (CRO), ... anonymization solution on October 4, 2017. Shadow is designed to assist ... with policy 0070 of the European Medicines Agency (EMA) in meeting ... ... ...
(Date:8/15/2017)... --  ivWatch LLC , a medical device company focused on improving ... of its ISO 13485 Certification, the global standard for medical device ... (ISO®). ... Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as it ...
(Date:6/30/2017)... ARLINGTON, Va. , June 30, 2017 /PRNewswire-USNewswire/ ... a leading developer and supplier of face and ... the ATA Featured Product provider program. ... created an innovative way to monitor a driver,s ... benefit greatly from being able to detect fatigue ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
Breaking Biology Technology: